These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 11555612)

  • 1. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
    Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
    Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y; Kyprianou N
    Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
    Yamamoto N; Imai J; Watanabe M; Hiroi N; Sugano S; Yoshino G
    Horm Metab Res; 2006 Mar; 38(3):159-66. PubMed ID: 16673206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
    Guo Y; Kyprianou N
    Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer.
    Kleeff J; Ishiwata T; Maruyama H; Friess H; Truong P; Büchler MW; Falb D; Korc M
    Oncogene; 1999 Sep; 18(39):5363-72. PubMed ID: 10498890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
    Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
    Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
    Ko Y; Banerji SS; Liu Y; Li W; Liang J; Soule HD; Pauley RJ; Willson JK; Zborowska E; Brattain MG
    J Cell Physiol; 1998 Aug; 176(2):424-34. PubMed ID: 9648930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
    Yagyu T; Kobayashi H; Wakahara K; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
    FEBS Lett; 2004 Oct; 576(3):408-16. PubMed ID: 15498571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
    Okamoto M; Oyasu R
    Cell Growth Differ; 1997 Aug; 8(8):921-6. PubMed ID: 9269901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
    Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
    Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.
    Ye SC; Foster JM; Li W; Liang J; Zborowska E; Venkateswarlu S; Gong J; Brattain MG; Willson JK
    Cancer Res; 1999 Sep; 59(18):4725-31. PubMed ID: 10493532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
    Deng X; Bellis S; Yan Z; Friedman E
    Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
    Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
    Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma.
    Löhr M; Schmidt C; Ringel J; Kluth M; Müller P; Nizze H; Jesnowski R
    Cancer Res; 2001 Jan; 61(2):550-5. PubMed ID: 11212248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
    Won J; Kim H; Park EJ; Hong Y; Kim SJ; Yun Y
    Cancer Res; 1999 Mar; 59(6):1273-7. PubMed ID: 10096559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
    Zhou R; Xiong B; Song H; Liu S; Wang X
    Oncol Rep; 2008 Dec; 20(6):1449-56. PubMed ID: 19020727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
    Peng B; Fleming JB; Breslin T; Grau AM; Fojioka S; Abbruzzese JL; Evans DB; Ayers D; Wathen K; Wu T; Robertson KD; Chiao PJ
    Clin Cancer Res; 2002 Nov; 8(11):3628-38. PubMed ID: 12429655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.